Simply removing pressure doesn't work, but youthful drug-taking prevents hereditary mid-life failure

Journal of Hypertension

Volumn 25, Issue 1, 2007, Pages 55-56

  McGrath, John C ^a,b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN ANTAGONIST; ANGIOTENSIN II; HYDRALAZINE; LOSARTAN; REACTIVE OXYGEN METABOLITE;

AGE; BLOOD PRESSURE REGULATION; EDITORIAL; HEART INJURY; HUMAN; HYPERTENSION; KIDNEY INJURY; LIFESTYLE; MORBIDITY; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

EID: 33845355844     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3280127606     Document Type: Editorial

References (12)

1. ALLHAT Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997.
2. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-153.
3. Paradis P, Dali-Youcef N, Paradis FW, Thibault G, Nemer M. Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodelling. Proc Natl Acad Sci U S A 2000; 97:931-936.
4. Yokoyama H, Averill DB, Brosnihan KB, Smith RD, Schiffrin EL, Ferrario CM. Role of blood pressure reduction in prevention of cardiac and vascular hypertrophy. Am J Hypertens 2005; 18:922-929.
5. Brilla CG, Janicki JS, Weber KT. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation 1991; 83:1771-1779.
6. Nishikawa K. Angiotensin AT1 receptor antagonism and protection against cardiovascular end-organ damage. J Hum Hypertens 1998; 12:301-309.
7. Baumann M, Janssen B, Hermans R, Peutz-Kootstra C, Witzke O, Smits J, Struijker Boudier H. Transient AT1 receptor-inhibition in prehypertensive SHR results in maintained cardiac protection until senescence. J Hypertens 2006; 24:207-215.
8. Barker DJ. Fetal programming of coronary heart disease. Trends Endocrinol Metab 2002; 13:364-368.
9. Racasan S, Braam B, Koomans HA, Joles JA. Programming blood pressure in adult SHR by shifting perinatal balance of NO and reactive oxygen species toward NO: the inverted Barker phenomenon. Am J Physiol Renal Physiol 2005; 288:F626-F636.
10. Paravicini TM, Touyz RM. Redox signaling in hypertension. Cardiovasc Res 2006; 71:247-258.
11. Gonzalez JM, Briones AM, Somoza B, Daly CJ, Vila E, Starcher B, et al. Postnatal alterations in elastic fiber organization precede resistance artery narrowing in SHR. Am J Physiol Heart Circ Physiol 2006; 291:H804-H812.
12. Di Nicolantonio R, Koutsis K, Westcott KT, Wlodek ME. Relative contribution of the prenatal versus postnatal period on development of hypertension and growth rate of the spontaneously hypertensive rat. Clin Exp Pharmacol Physiol 2006; 33:9-16.